Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen is seeking its next blockbuster medicine ... The medicine led to an average weight loss of about 20% after 52 weeks, with no plateau observed. And importantly, MariTide is administered once a ...

Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Amgen (NASDAQ:AMGN) and Zai Lab (NASDAQ:ZLAB) said on Monday that a late-stage trial testing the combination of bemarituzumab ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with sustained ...